Exploring the inhibition mechanism of interleukin-1-beta in gouty arthritis by polygonum cuspidatum using network pharmacology and molecular docking: A review.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
21 Jul 2023
21 Jul 2023
Historique:
medline:
24
7
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
Polygonum cuspidatum (Huzhang, HZ) is one of the commonly used traditional Chinese medicines for treating gouty arthritis (GA), but the specific mechanism is not clear. This study employed network pharmacology and molecular docking techniques to examine the molecular mechanisms underlying the therapeutic effects of HZ on GA. The network pharmacology approach, including active ingredient and target screening, drug-compound-target-disease network construction, protein-protein interaction (PPI) networks, enrichment analysis, and molecular docking, was used to explore the mechanism of HZ against GA. Ten active ingredients of HZ were predicted to interact with 191 targets, 14 of which interact with GA targets. Network pharmacology showed that quercetin, physovenine, luteolin, and beta-sitosterol are the core components of HZ, and IL (interleukin)-1β, IL-6, and tumor necrosis factor (TNF) are the core therapeutic targets. The mechanism of HZ in GA treatment was shown to be related to the IL-17 signaling pathway, NOD-like receptor signaling pathway, and Toll-like receptor signaling pathway, and is involved in the inflammatory response, positive regulation of gene expression, cellular response to lipopolysaccharide, and other biological processes. Molecular docking showed that all four core compounds had good binding properties to IL-1β, with luteolin and beta-sitosterol showing better docking results than anakinra, suggesting that they could be used as natural IL-1β inhibitors in further experimental studies. The mechanism of action of HZ against GA has multi-target and multi-pathway characteristics, which provides an important theoretical basis for the study of the active ingredients of HZ as natural IL-1β inhibitors.
Identifiants
pubmed: 37478249
doi: 10.1097/MD.0000000000034396
pii: 00005792-202307210-00044
pmc: PMC10662804
doi:
Substances chimiques
Luteolin
KUX1ZNC9J2
Drugs, Chinese Herbal
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e34396Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Sci Rep. 2015 Oct 15;5:15290
pubmed: 26469778
Mediators Inflamm. 2017;2017:3908061
pubmed: 28316374
Inflammopharmacology. 2020 Oct;28(5):1395-1400
pubmed: 32095979
J Proteomics. 2020 Feb 20;213:103613
pubmed: 31843688
Genome Biol. 2019 Sep 2;20(1):185
pubmed: 31477170
Int Immunopharmacol. 2022 Oct;111:109112
pubmed: 35932610
Arthritis Res Ther. 2017 Sep 15;19(1):204
pubmed: 28915838
J Ethnopharmacol. 2012 Aug 1;142(3):845-50
pubmed: 22732730
Front Immunol. 2018 Mar 01;9:399
pubmed: 29545806
Acta Pharm Sin B. 2023 Feb;13(2):678-693
pubmed: 36873170
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Nucleic Acids Res. 2019 Jan 8;47(D1):D1038-D1043
pubmed: 30445645
Arch Biochem Biophys. 2019 Jul 30;670:94-103
pubmed: 31255694
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Nucleic Acids Res. 2023 Jan 6;51(D1):D1373-D1380
pubmed: 36305812
J Ethnopharmacol. 2023 Jun 12;309:116306
pubmed: 36858276
Dis Markers. 2022 Dec 19;2022:5851412
pubmed: 36578443
Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i12-i19
pubmed: 29272514
Semin Arthritis Rheum. 2015 Aug;45(1):81-5
pubmed: 25795473
Phytomedicine. 2018 Mar 1;41:54-61
pubmed: 29519319
Nat Rev Rheumatol. 2022 Feb;18(2):97-111
pubmed: 34921301
Arthritis Res Ther. 2019 Nov 8;21(1):229
pubmed: 31703711
Nutrients. 2019 Dec 04;11(12):
pubmed: 31817107
Joint Bone Spine. 2017 Oct;84(5):541-546
pubmed: 27932279
Cell Rep. 2017 Feb 28;18(9):2077-2087
pubmed: 28249154
Bioinformatics. 2022 Feb 7;38(5):1452-1454
pubmed: 34864908
Trends Mol Med. 2016 Mar;22(3):230-241
pubmed: 26837266
J Ethnopharmacol. 2020 Apr 24;252:112606
pubmed: 31988013
Rheumatology (Oxford). 2021 Nov 3;60(11):e375-e377
pubmed: 34009241
Arthritis Res Ther. 2018 Jun 1;20(1):108
pubmed: 29855389
PLoS One. 2013 Dec 31;8(12):e83922
pubmed: 24391846
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Pharm Biol. 2021 Dec;59(1):1326-1333
pubmed: 34582722
Nat Rev Rheumatol. 2015 Nov;11(11):649-62
pubmed: 26150127
Ann Rheum Dis. 2023 Mar;82(3):416-427
pubmed: 36109143
Arch Immunol Ther Exp (Warsz). 2015 Dec;63(6):435-49
pubmed: 26062902
Database (Oxford). 2015 Apr 15;2015:bav028
pubmed: 25877637
Biochem Biophys Res Commun. 2018 Mar 11;497(3):897-902
pubmed: 29476737
Front Med (Lausanne). 2023 Jan 12;9:1089993
pubmed: 36714095